These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21188115)

  • 1. New developments in treatment of ovarian carcinoma: focus on trabectedin.
    Cassier PA; Duret A; Trédan O; Carrabin N; Méeus P; Treilleux I; Guastalla JP; Ray-Coquard I
    Cancer Manag Res; 2010 Oct; 2():233-42. PubMed ID: 21188115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin and its potential in the treatment of soft tissue sarcoma.
    Cassier PA; Dufresne A; Blay JY; Fayette J
    Ther Clin Risk Manag; 2008 Feb; 4(1):109-16. PubMed ID: 18728699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.
    Pignata S; Scambia G; Villanucci A; Naglieri E; Ibarbia MA; Brusa F; Bourgeois H; Sorio R; Casado A; Reichert D; Dopchie C; De Rivas B; de Sande LM
    Oncologist; 2021 Apr; 26(4):e658-e668. PubMed ID: 33289956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors.
    Villanucci A; Tavella K; Vannini L; Rossi V; Nobili S; Amunni G; Mazzei T; Mini E
    Mol Clin Oncol; 2018 Dec; 9(6):635-639. PubMed ID: 30546893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Data Brief; 2020 Jun; 30():105465. PubMed ID: 32346557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Lisyanskaya AS; Makhson AN; Rolski J; Gorbounova VA; Ghatage P; Bidzinski M; Shen K; Ngan HY; Vergote IB; Nam JH; Park YC; Lebedinsky CA; Poveda AM
    J Clin Oncol; 2010 Jul; 28(19):3107-14. PubMed ID: 20516432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
    Leporini C; Patanè M; Saullo F; Rende P; Gallelli L; Di Paola ED; Toscano R; Lucia M; Rossi M; De Sarro G; Russo E
    BioDrugs; 2014 Dec; 28(6):499-511. PubMed ID: 25209722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Romero I; Mallol P; Santaballa A; Del Campo JM; Mori M; González-Santiago S; Casado A; Vicente D; Ortega E; Herrero A; Guerra E; Barretina-Ginesta P; Rubio MJ; Martínez A; Bover I; Vidal L; Arcusa Á; Martín L; García Y; González-Martín A
    Anticancer Drugs; 2019 Jul; 30(6):628-635. PubMed ID: 31008727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
    Selle F; Heudel PE; Hardy-Bessard AC; Pozet A; Meunier J; Gladieff L; Lotz JP; Provansal M; Augereau P; Berton D; Bonichon-Lamichhane N; Orfeuvre H; Pautier P; Kalbacher E; Tazi Y; Spaeth D
    Anticancer Res; 2020 Jul; 40(7):3939-3945. PubMed ID: 32620635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Sehouli J; Alfaro V; González-Martín A
    Ann Oncol; 2012 Mar; 23(3):556-562. PubMed ID: 21734221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.